On January 26, 2024, the company "Ananta Medicare" participated in the online event "Respiratory Medicine"

Allergic diseases are quite common among the population today. This is due to a number of factors, primarily environmental factors and pollution of the surrounding environment with allergens of various origins.

Allergic rhinitis is a significant part of allergic diseases and characterized by allergic inflammation of the nasal mucosa. Allergic rhinitis has high social significance, as approximately 55% of patients experience serious impairments in quality of life, including negative effects on sleep, concentration, career, and personal life. The degree of sleep disturbances correlates directly with the severity of the disease, leading to decreased work productivity and social functioning, as well as the development of chronic fatigue syndrome, which in turn increases the risk of comorbidities.

Therefore, the treatment of allergic rhinitis is an important task of modern medicine.

The project addressed relevant issues in diagnosis and treatment of respiratory diseases to an audience of doctors from various specialties, including otolaryngologists, pulmonologists, allergologists, and family physicians.

The main expert in otolaryngology of the Department of Health of Kyiv, Honored Doctor of Ukraine, Head of the City Scientific and Practical Centre of Endoscopic Rhinolaryngology, Head of the ENT Department, Candidate of Medical Sciences, Associate Professor of the P.L. Shupyk National Medical Academy of Postgraduate Education, Bil Bohdan Nazarovych, presented a report on modern principles of treating allergic rhinitis. The expert covered in detail the etiology, pathogenesis, and main methods of treatment for allergic rhinitis, as well as emphasized the connection between allergic rhinitis and bronchial asthma. The speaker paid special attention to the features of using the modern medicinal product Allerginol Plus for allergic rhinitis and its advantages over other antiallergic medications.

Allerginol Plus is a fixed combination of two components - the antihistamine levocetirizine and montelukast, a leukotriene receptor anagonist. These two medicines in the composition of Allerginol Plus are synergistic in their pharmacological effect and enhance each other's action. Both components have clinically proven efficacy in allergic rhinitis.

The use of the combined Allerginol Plus provides as follows:

• more pronounced clinical effect in allergic diseases;
• reduces the need for glucocorticosteroids;
• improves pharmacoeconomic indicators of pharmacotherapy of allergic diseases;
• improves the quality of patients' lives.

Allerginol Plus - double power against allergy!

Registration certificate No. UA/14440/01/01